Roche has made a significant announcement, revealing its commitment of USD 50 billion to be invested in the United States over the next five years. This investment aims to enhance the company’s already substantial presence in the US, which includes 13 manufacturing and 15 research and development (R&D) sites across its Pharmaceutical and Diagnostics Divisions.
The planned investments are poised to create over 12,000 new jobs in the US, featuring nearly 6,500 construction positions, along with 1,000 new roles at the facilities that will be expanded and developed. Roche currently employs more than 25,000 individuals across 24 sites in eight states.
As part of their comprehensive investment strategy, Roche plans to strengthen its manufacturing and distribution capabilities in various locations including Kentucky, Indiana, New Jersey, Oregon, and California.
Key projects in the pipeline consist of a groundbreaking gene therapy manufacturing facility set to emerge in Pennsylvania, and an expansive 900,000 square foot manufacturing centre dedicated to next-generation weight loss medicines, with its location yet to be announced. Furthermore, a new facility for continuous glucose monitoring will be established in Indiana.
Roche also intends to launch a state-of-the-art R&D centre in Massachusetts, which will focus on cutting-edge artificial intelligence (AI) research and act as a hub for advancing cardiovascular, renal, and metabolism projects in R&D.
Existing pharmaceutical and diagnostics R&D centres in Arizona, Indiana, and California will undergo significant expansions and upgrades as part of this expansive investment plan.
Thomas Schinecker, CEO of Roche Group, expressed the company’s dedication to the US market, stating, “Roche is a Swiss company with a strong heritage in more than 130 countries globally. Today’s announced investments underscore our long-standing commitment to research, development and manufacturing in the US. We are proud of our 110 year legacy in the United States which has been a key driver for jobs, innovation and the creation of intellectual property in the US, across both our Pharmaceutical and Diagnostics Divisions. Our investments of USD 50 billion over the next five years will lay the foundation for our next era of innovation and growth, benefiting patients in the US and around the world.”
Once the new and expanded manufacturing capacity is operational, Roche anticipates that it will export more medicines from the US than it imports. Notably, the company’s diagnostics division currently enjoys an export surplus from the US to other countries.
Founded in 1896 in Basel, Switzerland, Roche has evolved to become one of the world’s largest biotechnology companies and the global leader in in-vitro diagnostics. With a commitment to scientific excellence, Roche is dedicated to discovering and developing innovative medicines and diagnostics to improve the health and well-being of individuals globally. The company has also been a pioneer in personalized healthcare, constantly striving to transform and enhance healthcare delivery.
Sustainability is a core principle at Roche, which has integrated it into its operations for over 125 years. The company aims to contribute significantly to society by developing ground-breaking medicines and diagnostics that promote healthier lives. Additionally, Roche is devoted to the Science Based Targets initiative and the Sustainable Markets Initiative, aspiring to achieve net zero by 2045.
Roche’s US operations include its wholly owned subsidiary, Genentech, and significant ownership in Chugai Pharmaceutical in Japan. For further details about Roche and its investments, please visit their official website at www.roche.com.
image source from：https://www.roche.com/media/releases/med-cor-2025-04-22
